Share on

Middle East and Africa Cytokine Based Therapies and Inhibitors Market Research Report – Segmented By Type, Therapeutic Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 7996
Pages: 145
Formats: report pdf report excel report power bi report ppt

The size of the Middle East and Africa Cytokine Based Therapies and Inhibitors Market is predicted to grow at a healthy rate between 2022 to 2027.

Cytokines-based therapies and inhibitors play an essential role in cancer pathogenesis because they promote growth, attenuate apoptosis, and facilitate invasion and metastasis. Due to these factors, scientists are studying cytokines to develop novel engineered cytokine mutants, chimeric antibody and cytokine fusion proteins, cancer vaccines, checkpoint inhibitors, and monoclonal antibodies directed against cancer. Additionally, in recent years, FDA approval of cytokine-based anti-inflammatory biologics, such as anti-TNF-α biologics, has positively affected the market.

The market is further estimated to grow exponentially attributed to huge investments from various governments, raising awareness, and increasing the cancer incidence rate and significant key players in the research and development. Among the GCC countries, nearly 32,291 cases of cancer were diagnosed in the region, with 16,342 cases for males and 15,949 cases for females. Moreover, cytokines are proven to succeed as vaccines and other treatment procedures due to the increasing number of therapeutic, diagnostic, and prophylactic applications.

In 2020-2022, the cytokine storm was the leading cause of multiple organ failure in COVID-19 infections, which drove the market. In addition, excessive infiltration of inflammatory cells such as monocytes and neutrophils has led to prominent lung damage, which is fatal. Hence, many researchers focus on generating various therapies to limit the symptoms. This has created numerous lucrative opportunities for the cytokine inhibitors and therapeutics market in the MEA region.

However, a few of the significant factors affecting the market's growth in this region are the shortage of qualified professionals and the high cost associated with therapy coupled with an inadequate reimbursement system. In addition, other factors such as insufficient immune response caused by cytokines, lack of skilled labor, extensive ongoing research with strict regulation, and short duration of activity of cytokine drugs will challenge the market growth in the years to come.

This research report on the Middle East and Africa cytokine-based therapies and inhibitors market has been segmented and sub-segmented into the following categories.

By Type:

  • Interleukins            
  • Tumor necrosis factor        
  • Epidermal growth factor   
  • Interferon               
  • Chemokine    

By Therapeutic Application:

  • Inflammatory and immune disorders          
  • Cancer and malignancies   
  • Infectious diseases              
  • Others

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle Eastern region dominates the MEA market due to the growing prevalence of cancer, improving healthcare facilities, growing R&D and clinical trials, and large pharmaceutical industry. In addition, numerous studies in animal tumor models have shown that cytokines have broad antitumor activity, which has resulted in several cytokine-based approaches for cancer treatment. Within the GCC region, in 2020, the highest proportion of trials took place in Iran, with 79.34% of all trials, and Egypt recorded the highest percentage of 24.7%. Israel and Saudi Arabia had the second-highest percentage of 9.1% and 3.4%.

Meanwhile, the African region is also anticipated to grow steadily due to improving awareness and healthcare facilities, high prevalence of diseases, and funds for R&D during the aforementioned forecast period. In 2020, Africa increased 114% for various infectious disease-related trials. And South Africa and Uganda accounted for a significant share of the market growth during the analysis period. These numbers are projected to increase with R&D in cancer treatment, coupled with fewer side effects. This factor is expected to support the market share in the MEA region.

KEY MARKET PLAYERS:

Some of the significant players in the Cytokine Based Therapies and Inhibitors market are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson, and Amgen Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample